Rocket Lab Gains 6.3% in the Past Month: How to Play the Stock?

Rocket Lab (RKLB) shares rose 6.3% last month, significantly outperforming its industry, driven by its 70th Electron launch, the opening of Launch Complex 3 for the Neutron rocket, and the $275 million acquisition of Geost, expanding its defense and sensor capabilities. While the company projects strong revenue and earnings growth for 2025-2026 and expects the Neutron program to broaden its market reach by H2 2025, investors face notable risks including elevated operating expenses, persistent losses, and a premium valuation of 28.44x forward Price/Sales compared to an industry average of 9.55x.

Analysis

Rocket Lab (RKLB) has demonstrated significant operational momentum and stock outperformance, gaining 6.3% in the past month while its industry benchmark, the Zacks Aerospace-Defense Equipment industry, declined 2.5%. This performance is underpinned by key strategic achievements, including the 70th successful launch of its Electron rocket, reinforcing its leadership in the small orbital launch market. The company is also expanding its strategic capabilities through the $275 million acquisition of Geost, a developer of EO/IR sensor systems, and by securing $23.9 million in CHIPS Act funding to bolster domestic production of space-grade solar cells. These moves enhance its role as a prime contractor for defense initiatives and secure its supply chain.

Looking forward, the primary growth catalyst is the development of the reusable Neutron rocket, which targets the larger medium-lift launch market. The recent opening of Launch Complex 3 is a critical step toward a first flight anticipated in the second half of 2025. Consensus estimates project strong top-line growth of 34.7% in 2025 and 46.7% in 2026. However, these growth prospects are tempered by significant risks. The company continues to incur substantial operating expenses and net losses due to heavy investment in new technologies, which have outpaced revenue growth. Furthermore, RKLB shares trade at a considerable premium, with a forward 12-month Price-to-Sales ratio of 28.44x, far exceeding the industry average of 9.55x, suggesting high expectations are already priced into the stock.

Key Decisions for Investors

• Given the stock's premium valuation at a 28.44x forward P/S multiple, prospective investors should exercise caution and may consider waiting for a more attractive entry point or a pullback.
• Current shareholders could justify holding their positions based on the company's strong operational execution, demonstrated by its consistent launch cadence and strategic acquisitions that are expanding its addressable market.
• Monitor key execution milestones for the Neutron program, as any delays beyond the targeted H2 2025 first flight could negatively impact the long-term growth narrative and valuation.
• Closely track quarterly earnings reports for any signs of improving operating leverage, as the company's ability to narrow its losses while scaling revenue is critical to justifying its current premium.